Skip to main content

Table 1 Baseline characteristics of persons living with HIV in the US receiving antiretroviral agents, stratified by exposure to abacavir, in the IMS PharMetric Plus claims database from October 1, 2009 through December 31, 2014

From: Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study

Characteristic Exposed to abacavir (n = 8530) Exposed to other ARV agents (reference group) (n = 64,203)
Age, median (IQR) 48 (43–54) 46 (39–52)
Male 6889 (80.76) 52,402 (81.62)
Region
 East 2057 (24.11) 15,336 (23.89)
 Mid-West 1370 (16.06) 12,104 (18.85)
 South 3986 (46.73) 29,179 (45.45)
 West 1117 (13.09) 7584 (11.81)
Year of ART initiation in the database
 2009 3590 (42.09) 20,440 (31.84)
 2010 1120 (13.13) 8578 (13.36)
 2011 1147 (13.45) 9121 (14.21)
 2012 801 (9.39) 7824 (12.19)
 2013 643 (7.54) 7259 (11.39)
 2014 1229 (14.41) 10,981 (17.10)
Ever substance abuse 1290 (15.12) 11,837 (18.44)
Ever alcohol abuse 273 (3.20) 2750 (4.28)
Ever tobacco use/smoking 1198 (14.04) 10,385 (16.18)
Body mass index > 24.9 116 (1.36) 1130 (1.76)
Essential hypertension 766 (8.98) 5026 (7.83)
Diabetes mellitus 366 (4.29) 2049 (3.19)
Chronic Kidney Disease 265 (3.11) 492 (0.77)
Dyslipidemia 820 (9.61) 5552 (8.65)
Lipodystrophy 36 (0.42) 129 (0.20)
Pre-existing heart diseasea 242 (2.84) 1768 (2.75)
Receipt of medications for heart diseaseb 819 (9.60) 4816 (7.50)
History of stroke 25 (0.29) 160 (0.25)
Symptomatic HIV disease 2313 (27.12) 18,839 (29.34)
Hepatitis B 69 (0.81) 612 (0.95)
Hepatitis C 141 (1.65) 896 (1.40)
History of cancer 438 (5.13) 4152 (6.47)
  1. All reported as N (%) unless otherwise stated
  2. aPrior myocardial infarction, heart failure, cardiac dysrhythmias, and atherosclerosis
  3. bAspirin, beta-blocker, statins, angiotensin converting enzyme inhibitor, angiotensin receptor blocker, calcium channel blocker